Yervoy
GSK melanoma drugs beat rival in new study
July 18, 2014Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma
GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …
Roche combination drug for melanoma impresses
July 14, 2014Research and Development, Sales and Marketing GSK, Roche, Yervoy, braf, mekinist. MEK, melanoma
Roche’s investigational melanoma drug cobimetinib has helped late-stage patients live longer when used in combination with its established skin cancer …
New BMS cancer treatment shines
June 25, 2014Research and Development, Sales and Marketing ASCO, BMS, Cancer, Yervoy, braf, melanoma, nivolumab
Bristol-Myers Squibb’s investigational cancer treatment nivolumab has helped patients with the deadliest form of skin cancer to live longer. The …
NICE recommends Yervoy
June 13, 2014Sales and Marketing BMS, Cancer, Dillon, NHS, NICE, Yervoy, melanoma
Bristol-Myers Squibb has received a lift from the UK’s drugs watchdog, which has recommended its vaccine Yervoy as a first-line …
BMS hopes for Yervoy sequel with new deal
March 18, 2014Research and Development, Sales and Marketing Avapro, BMS, Plavix, Yervoy, five prime, immune-oncology
Bristol-Myers Squibb has announced a new research and development deal with Five Prime Therapeutics aimed at discovering potentially new cancer …
Amgen melanoma vaccine shrinks tumours
March 17, 2014Research and Development, Sales and Marketing Amgen, Cancer, Yervoy, melanoma, t-vec
Amgen’s investigational cancer vaccine T-vec has managed to shrink the size of advanced melanoma tumours in a late-stage trial. The …
NICE restricts Yervoy use
February 25, 2014Sales and Marketing BMS, Cancer, NHS, NICE, Yervoy, melanoma
Bristol-Myers Squibb has been dealt a blow by NICE after the UK cost watchdog recommended that the use of skin …
BMS revenue drops in 2013
January 27, 2014Sales and Marketing AZ, BMS, Yervoy, diabetes, hep C, q4
Bristol-Myers’ Squibb’s revenue has fallen 7% year-on-year to $16.4 billion during 2013. Turnover rose 6% to $4.4 billion in the …
Yervoy setback in prostate cancer
September 16, 2013Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer
GSK cancer vaccine fails in Phase III
September 5, 2013Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III
GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …
GSK’s skin cancer pill Tafinlar gets EMA approval
September 3, 2013Sales and Marketing BMS, GSK, Tafinlar, Yervoy, melanoma
GSK has been granted EMA marketing authorisation for its new metastatic melanoma drug Tafinlar. The EMA’s decision on Tafinlar (dabrafenib) …
Eight in ten survive skin cancer
July 22, 2013Research and Development, Sales and Marketing Yervoy, Zelboraf, melanoma, skin cancer
The vast majority of men and women diagnosed with malignant melanoma are now surviving the disease, according to a new …
NICE hails ‘breakthrough’ skin cancer treatments
November 2, 2012Sales and Marketing BMS, NICE, Roche, Yervoy, Zelboraf
Two new skin cancer drugs have been recommended by NICE, which hailed the drugs as ‘breakthrough treatments’. Bristol-Myers Squibb’s Yervoy …
BMS highlights Yervoy survival data
October 1, 2012Research and Development, Sales and Marketing BMS, Roche, Yervoy, Zelboraf
Bristol-Myers Squibb’s melanoma drug Yervoy helps patients survive for longer than if they are receiving standard chemotherapy alone, according to …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
